Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202371741> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W3202371741 endingPage "265" @default.
- W3202371741 startingPage "263" @default.
- W3202371741 abstract "Spinal muscular atrophy (SMA) is a progressive neurodegenerative disease due to homozygous loss-of-function of the survival motor neuron gene SMN 1 with absence of the functional SMN protein. Nusinersen, a costly intrathecally administered drug approved in 2017 in Europe, induces alternative splicing of the SMN2 gene, which then produces functional SMN protein, whose amount generally increases with the number of SMN2 gene copies.We retrospectively collected data from consecutive wheelchair-bound adults with SMA managed at a single center in 2018–2020. The following were collected at each injection, on days 1, 14, 28, 63, 183, and 303: 32-item Motor Function Measurement (MFM) total score and D2 and D3 subscores; the Canadian Occupational Performance Measure (COPM) performance and satisfaction scores; and lung function tests. The patients were divided into two groups based on whether their MFM total score was < or ≥ the mean (15.6%). Adverse events were recorded.We identified 18 patients who received 4 to 8 Nusinersen injections. No significant improvements occurred over time in any of the MFM scores or lung function test results, which did not differ between groups. The COPM performance score improved significantly from day 0 to day 303 in the high-MFM group and the COPM satisfaction score in the overall population from D0 to D183. Half the patients achieved the minimal clinically important difference for both COPM scores.The overall stability of conventional motor assessment in this population with advanced disabilities is encouraging to use more sensitive tools based on self-perception and autonomy in daily life activities, such as COPM. Our finding of a significant COPM performance score improvement from days 0 to 303 only in the patients with initial MFM-32 scores above the mean in the population suggests that the severity of the baseline disabilities may affect treatment efficacy.IV, retrospective observational cohort study." @default.
- W3202371741 created "2021-10-11" @default.
- W3202371741 creator A5009969425 @default.
- W3202371741 creator A5016342397 @default.
- W3202371741 creator A5031774317 @default.
- W3202371741 creator A5058479274 @default.
- W3202371741 creator A5067313839 @default.
- W3202371741 creator A5078286408 @default.
- W3202371741 date "2022-03-01" @default.
- W3202371741 modified "2023-10-18" @default.
- W3202371741 title "Late moyamoya-like angiopathy syndrome revealing MAP2K1 Noonan syndrome" @default.
- W3202371741 cites W1979291105 @default.
- W3202371741 cites W2075301039 @default.
- W3202371741 cites W2095205520 @default.
- W3202371741 cites W2162849071 @default.
- W3202371741 cites W2603085056 @default.
- W3202371741 cites W2803763200 @default.
- W3202371741 cites W4230421038 @default.
- W3202371741 doi "https://doi.org/10.1016/j.neurol.2021.07.017" @default.
- W3202371741 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34565623" @default.
- W3202371741 hasPublicationYear "2022" @default.
- W3202371741 type Work @default.
- W3202371741 sameAs 3202371741 @default.
- W3202371741 citedByCount "0" @default.
- W3202371741 crossrefType "journal-article" @default.
- W3202371741 hasAuthorship W3202371741A5009969425 @default.
- W3202371741 hasAuthorship W3202371741A5016342397 @default.
- W3202371741 hasAuthorship W3202371741A5031774317 @default.
- W3202371741 hasAuthorship W3202371741A5058479274 @default.
- W3202371741 hasAuthorship W3202371741A5067313839 @default.
- W3202371741 hasAuthorship W3202371741A5078286408 @default.
- W3202371741 hasConcept C114614502 @default.
- W3202371741 hasConcept C126322002 @default.
- W3202371741 hasConcept C161921814 @default.
- W3202371741 hasConcept C1862650 @default.
- W3202371741 hasConcept C2778558090 @default.
- W3202371741 hasConcept C2779134260 @default.
- W3202371741 hasConcept C2908647359 @default.
- W3202371741 hasConcept C33923547 @default.
- W3202371741 hasConcept C71924100 @default.
- W3202371741 hasConcept C99454951 @default.
- W3202371741 hasConcept C99508421 @default.
- W3202371741 hasConceptScore W3202371741C114614502 @default.
- W3202371741 hasConceptScore W3202371741C126322002 @default.
- W3202371741 hasConceptScore W3202371741C161921814 @default.
- W3202371741 hasConceptScore W3202371741C1862650 @default.
- W3202371741 hasConceptScore W3202371741C2778558090 @default.
- W3202371741 hasConceptScore W3202371741C2779134260 @default.
- W3202371741 hasConceptScore W3202371741C2908647359 @default.
- W3202371741 hasConceptScore W3202371741C33923547 @default.
- W3202371741 hasConceptScore W3202371741C71924100 @default.
- W3202371741 hasConceptScore W3202371741C99454951 @default.
- W3202371741 hasConceptScore W3202371741C99508421 @default.
- W3202371741 hasIssue "3" @default.
- W3202371741 hasLocation W32023717411 @default.
- W3202371741 hasLocation W32023717412 @default.
- W3202371741 hasOpenAccess W3202371741 @default.
- W3202371741 hasPrimaryLocation W32023717411 @default.
- W3202371741 hasRelatedWork W2152873633 @default.
- W3202371741 hasRelatedWork W2153861281 @default.
- W3202371741 hasRelatedWork W2528264181 @default.
- W3202371741 hasRelatedWork W3093669834 @default.
- W3202371741 hasRelatedWork W3118156846 @default.
- W3202371741 hasRelatedWork W3155093741 @default.
- W3202371741 hasRelatedWork W3163552393 @default.
- W3202371741 hasRelatedWork W3193767101 @default.
- W3202371741 hasRelatedWork W4224939690 @default.
- W3202371741 hasRelatedWork W1278871635 @default.
- W3202371741 hasVolume "178" @default.
- W3202371741 isParatext "false" @default.
- W3202371741 isRetracted "false" @default.
- W3202371741 magId "3202371741" @default.
- W3202371741 workType "article" @default.